• Je něco špatně v tomto záznamu ?

Metabolic status of CSF distinguishes rats with tauopathy from controls

R. Karlíková, K. Mičová, L. Najdekr, A. Gardlo, T. Adam, P. Majerová, D. Friedecký, A. Kováč,

. 2017 ; 9 (1) : 78. [pub] 20170921

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024633

BACKGROUND: Tauopathies represent heterogeneous groups of neurodegenerative diseases that are characterised by abnormal deposition of the microtubule-associated protein tau. Alzheimer's disease is the most prevalent tauopathy, affecting more than 35 million people worldwide. In this study we investigated changes in metabolic pathways associated with tau-induced neurodegeneration. METHODS: Cerebrospinal fluid (CSF), plasma and brain tissue were collected from a transgenic rat model for tauopathies and from age-matched control animals. The samples were analysed by targeted and untargeted metabolomic methods using high-performance liquid chromatography coupled to mass spectrometry. Unsupervised and supervised statistical analysis revealed biochemical changes associated with the tauopathy process. RESULTS: Energy deprivation and potentially neural apoptosis were reflected in increased purine nucleotide catabolism and decreased levels of citric acid cycle intermediates and glucose. However, in CSF, increased levels of citrate and aconitate that can be attributed to glial activation were observed. Other significant changes were found in arginine and phosphatidylcholine metabolism. CONCLUSIONS: Despite an enormous effort invested in development of biomarkers for tauopathies during the last 20 years, there is no clinically used biomarker or assay on the market. One of the most promising strategies is to create a panel of markers (e.g., small molecules, proteins) that will be continuously monitored and correlated with patients' clinical outcome. In this study, we identified several metabolic changes that are affected during the tauopathy process and may be considered as potential markers of tauopathies in humans.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024633
003      
CZ-PrNML
005      
20180712091838.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13195-017-0303-5 $2 doi
035    __
$a (PubMed)28934963
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Karlíková, Radana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
245    10
$a Metabolic status of CSF distinguishes rats with tauopathy from controls / $c R. Karlíková, K. Mičová, L. Najdekr, A. Gardlo, T. Adam, P. Majerová, D. Friedecký, A. Kováč,
520    9_
$a BACKGROUND: Tauopathies represent heterogeneous groups of neurodegenerative diseases that are characterised by abnormal deposition of the microtubule-associated protein tau. Alzheimer's disease is the most prevalent tauopathy, affecting more than 35 million people worldwide. In this study we investigated changes in metabolic pathways associated with tau-induced neurodegeneration. METHODS: Cerebrospinal fluid (CSF), plasma and brain tissue were collected from a transgenic rat model for tauopathies and from age-matched control animals. The samples were analysed by targeted and untargeted metabolomic methods using high-performance liquid chromatography coupled to mass spectrometry. Unsupervised and supervised statistical analysis revealed biochemical changes associated with the tauopathy process. RESULTS: Energy deprivation and potentially neural apoptosis were reflected in increased purine nucleotide catabolism and decreased levels of citric acid cycle intermediates and glucose. However, in CSF, increased levels of citrate and aconitate that can be attributed to glial activation were observed. Other significant changes were found in arginine and phosphatidylcholine metabolism. CONCLUSIONS: Despite an enormous effort invested in development of biomarkers for tauopathies during the last 20 years, there is no clinically used biomarker or assay on the market. One of the most promising strategies is to create a panel of markers (e.g., small molecules, proteins) that will be continuously monitored and correlated with patients' clinical outcome. In this study, we identified several metabolic changes that are affected during the tauopathy process and may be considered as potential markers of tauopathies in humans.
650    _2
$a zvířata $7 D000818
650    _2
$a apoptóza $x genetika $7 D017209
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a mozek $x metabolismus $x patologie $7 D001921
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolomika $7 D055432
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani inbrední SHR $7 D011918
650    _2
$a potkani transgenní $7 D055647
650    _2
$a tauopatie $x mok mozkomíšní $x diagnóza $x genetika $7 D024801
650    _2
$a proteiny tau $x genetika $x metabolismus $7 D016875
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mičová, Kateřina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
700    1_
$a Najdekr, Lukáš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
700    1_
$a Gardlo, Alžběta $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
700    1_
$a Adam, Tomáš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic. Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
700    1_
$a Majerová, Petra $u Institute of Neuroimmunology, Slovak Academy of Sciences, Dúbravská cesta 9, 84510, Bratislava, Slovak Republic. AXON Neuroscience R&D, Dvořákovo nábrežie 10, 811 02, Bratislava, Slovak Republic.
700    1_
$a Friedecký, David $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic. Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
700    1_
$a Kováč, Andrej $u Institute of Neuroimmunology, Slovak Academy of Sciences, Dúbravská cesta 9, 84510, Bratislava, Slovak Republic. andrej.kovac@savba.sk. AXON Neuroscience R&D, Dvořákovo nábrežie 10, 811 02, Bratislava, Slovak Republic. andrej.kovac@savba.sk.
773    0_
$w MED00172451 $t Alzheimer's research & therapy $x 1758-9193 $g Roč. 9, č. 1 (2017), s. 78
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28934963 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180712092131 $b ABA008
999    __
$a ok $b bmc $g 1316764 $s 1021554
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 9 $c 1 $d 78 $e 20170921 $i 1758-9193 $m Alzheimer's research & therapy $n Alzheimers Res Ther $x MED00172451
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...